Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10460416 | 0.94 | TDP1 (0.50) | OPRD1SLC6A2SLC6A4SLC6A3TDP1 | |
| SCHEMBL5491850 | 0.93 | MMP1 (0.49) | OPRD1SLC6A2SLC6A4SLC6A3TDP1 | |
| Hydrochloric Acid SCHEMBL10460896 | 0.90 | TDP1 (0.51) | OPRD1SLC6A2SLC6A4SLC6A3TDP1 | |
| SCHEMBL30149783 | 0.87 | HTR2C (0.52) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21382309 | 0.87 | HTR2C (0.52) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21381779 | 0.87 | HTR2C (0.52) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21382077 | 0.87 | HTR2C (0.52) | OPRD1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21382073 | 0.86 | TDP1 (0.44) | SLC6A2SLC6A4SLC6A3TDP1 | |
| SCHEMBL21381653 | 0.86 | TDP1 (0.44) | SLC6A2SLC6A4SLC6A3TDP1 | |
| SCHEMBL21382050 | 0.86 | TDP1 (0.44) | SLC6A2SLC6A4SLC6A3TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420961-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2022-08-23 | — | — | US | disclosed |
| EP-3717477-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-07-20 | — | — | EP | disclosed |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2020-12-17 | — | — | US | disclosed |
| EP-3717477-A1 | NEW HETEROCYCLIC COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-10-07 | — | — | EP | disclosed |
| CN-111386269-A | Novel heterocyclic compound | 豪夫迈·罗氏有限公司 | 2020-07-07 | — | — | CN | disclosed |
| US-4105849-A | [(Substituted )phenyl]phenylmethyl-1-(dialkylaminoalkyl)piperidines | G. D. SEARLE & CO. (US) | 1978-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420961-B2 | Heterocyclic compounds | LPXN, MLX, CCNY | OPRD1 1395/4885SLC6A2 4377/4885SLC6A4 4397/4885 |
| US-20200392125-A1 | HETEROCYCLIC COMPOUNDS | LPXN, MLX, CCNY | OPRD1 1395/4885SLC6A2 4377/4885SLC6A4 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.